Hugel, Inc. (KOSDAQ:145020)

Market Cap	2.74T -27.2%
Revenue (ttm)	425.11B +14.0%
Net Income	140.87B +3.7%
EPS	12,820.16 +6.9%
Shares Out	10.80M
PE Ratio	19.81
Forward PE	20.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,621
Average Volume	66,383
Open	266,000
Previous Close	265,500
Day's Range	244,000 - 267,000
52-Week Range	208,500 - 392,000
Beta	0.54
RSI	44.13
Earnings Date	May 7, 2026

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 594
• Stock Exchange: KOSDAQ
• Ticker Symbol: 145020

Financial Performance

In 2025, Hugel's revenue was 425.11 billion, an increase of 13.96% compared to the previous year's 373.05 billion. Earnings were 140.87 billion, an increase of 3.72%.